Weight-loss medications, including popular brands like Wegovy, Mounjaro, and Ozempic, are showing an unexpected side effect: a significant reduction in alcohol consumption and cravings for many users. Individuals taking these drugs, which contain semaglutide or tirzepatide and mimic the natural hormone GLP-1 to suppress appetite, report a diminished desire for alcohol, with some finding they physically cannot drink as much as before.

This phenomenon is drawing attention from researchers, who are exploring the link between these GLP-1 receptor agonist drugs and changes in alcohol intake. The medications work by making users feel fuller for longer, aiding in weight loss, but early scientific findings suggest they may also influence the brain's reward system, potentially dampening cravings not only for food but also for substances like alcohol and nicotine.

Early research indicates that these drugs could play a role in managing alcohol use disorder. A small-scale study published in 2025 by Dr. Christian Hendershot of the University of South Carolina found that participants with alcohol use disorder experienced reduced cravings while taking Ozempic. More recently, a study from the University of Colorado Anschutz suggested that GLP-1 medications, even in pill form, led to fewer instances of heavy drinking among individuals with mild to moderate alcohol use disorder.

The implications of these findings are substantial, potentially offering a new avenue for addressing alcohol consumption issues alongside weight management. As more research emerges, these medications could become a significant tool in public health strategies, though experts caution that more extensive studies are needed to confirm these effects and understand long-term impacts.

Users of these medications have shared varied experiences. Some report a complete cessation of alcohol cravings, while others note that alcohol now makes them feel nauseous or uncomfortably full, or that they become intoxicated more quickly. For Lisa Rees, 46, from South Wales, the reduction in alcohol intake has been a welcome, albeit unexpected, benefit. She previously consumed up to two bottles of wine on a night out and six to eight bottles weekly, sometimes worrying about her health. Since starting Wegovy in April, her consumption has more than halved, allowing her to remain socially engaged without excessive drinking.

For years, alcohol played a significant role in Rees's social life, and past attempts to cut back led to reduced social invitations. The current situation allows her to enjoy a few glasses of wine socially without the compulsion to drink more, maintaining her involvement in social events while moderating her intake. This contrasts with her previous pattern, where she might have consumed two bottles of wine plus vodka mixers at a day festival, but now finds herself drinking only three glasses of wine over nine hours.

Warren Thomas, 45, from Colchester, also experienced changes. He used to enjoy occasional beers after work and monthly heavy drinking sessions with friends. While the source material does not detail his specific changes in alcohol consumption due to the medication, his experience is part of the broader trend being observed.

NHS guidelines recommend no more than 14 units of alcohol per week, roughly six medium glasses of wine or six pints, to mitigate long-term health risks such as liver damage, high blood pressure, and increased cancer risk. The observed effects of weight-loss medications suggest a potential future where managing both weight and alcohol consumption could be addressed simultaneously, though more comprehensive clinical trials are necessary to validate these preliminary observations and establish clear treatment protocols.